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Abstract  
A series of triarylolefins bearing the combretastatin A-4 and the isocombretastatin A-4 cores were synthesized and 
evaluated. The cooperative ortho-effect of a labile bromine atom in the regioselective hydrostannation of unsymmetrical 
diarylalkynes leading to stereo-defined triarylolefins is presented. 
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1. Introduction 
The microtubule system of eukaryotic cells is an important target for the development of anticancer agents. 
Consequently, perturbation of normal tubulin assembly/disassembly is a popular target for new chemotherapeutic 
agents[1,2] Examples of clinically used antimitotic agents are paclitaxel, which promoted microtubules polymerization 
and inhibits microtubules depolymerization, and vincristine which inhibits microtubules assembly.[3,4] However, 
despite their potent antitumor activities, these drugs have undesirable side effects[5,6] and are subject to multidrug 
resistance.[7,8]  
In recent years, there has been more and more interest in the search of antitumor molecules of easy synthesis, with high 
efficacy and low side effects. Combretastatin A-4 (CA-4), a naturally occurring stilbene, extracted from the South 
African willow Combretum caffrum[9,10] is the most studied substance as a highly potent inhibitor of tubulin 
assembly.[11-13] Moreover, CA-4 displays strong cytotoxicities (nanomolar level) against a large panel of human 
cancer cells, including multi-drug-resistant cell lines.[14,15] Additionally, CA-4P[16-19] the water-soluble prodrug of 
CA-4, as well as AC-7739 and its amino acid derivative AVE-8062[20] have been demonstrated to cause a rapid and 
selective vascular shutdown in established tumors in vivo, consistent with an antivascular mechanism of action.[21-27] 
Currently, CA-4P[28] either as a single agent or in combination therapy is undergoing several advanced clinical trials 
worldwide for the treatment of age-related macular degeneration or anaplastic thyroid cancer. 
 
FIGURE 1 
 
Despite their remarkable anticancer activity, these Z-stilbene compounds are prone to double bond isomerization during 
storage and administration. The E-isomers display dramatically reduced inhibition of cancer cell growth and tubulin 
assembly.[29] In our efforts to discover novel tubulin assembly inhibitors,[30-32] we recently found that 
isocombretastatin A-4 (isoCA-4), the third and “forgotten” structural isomer of the natural product, displayed biological 
activities comparable to that of CA-4.[33,34] This substance having a 1,1-diarylethylene scaffold is easy to 
synthesize[35,36] at a multi grams scale without the need to control the olefin geometry. By structural modifications on 
the B ring, we have also identified other promising antiproliferative agents such as isoFCA-4 and isoNH2CA-4 (Figure 
1).[37] In addition, these apoptosis inductors substances were found to inhibit microtubules formation and to induce cell 
cycle arrest in G2/M phase. To combine the anticancer effects of CA-4 and isoCA-4 within a single substance (e.g.; 1h), 
we have synthesized a variety of hybrids 1 that bear, from one hand, the basic skeleton of CA-4 and, on the other hand, 
the one of isoCA-4 (Figure 1). Moreover, these compounds 1 may be regarded as Tamoxifen[38] or trisubstituted 
Combretastatin analogues of high antiproliferative activity.[39-41] The potencies of newly synthesized trisubstituted 
olefins 1 were evaluated for their capacity to inhibit cancer cellular growth and, to act as potential antimitotic agents. 
2. Results and discussion 
The strategy envisioned to prepare the target triarylolefins 1 involves a three step-sequence by achieving a 
regioselective hydrostannation of diarylalkynes (Scheme 1). Further direct Stille reaction or sequential iodolysis-
Negishi coupling would provide 1. 
 
SCHEME 1 
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At the outset of this work, the synthesis of triarylolefin 1a (Scheme 2) was first examined from symmetrically 
diarylalkyne 2 easily available by Sonogashira-Linstrumelle coupling reaction.[42,43] Palladium-catalyzed 
hydrostannation of 2 was achieved using Bu3SnH (1.2 eq) in THF at room temperature in the presence of PdCl2(PPh3)2 
(1 mol%) to give vinylstannane 3 in good yield (79%).[44-47] Subsequent direct coupling of 3 with 3,4,5-
trimethoxyiodobenzene under modified Stille conditions[48] provided a moderate 54% isolated yield of 1a. In order to 
increase the overall yield of 1a, we next evaluated a halodestannylation[49]-Negishi coupling sequence.[50,51] 
Iododestannylation of 3 with molecular iodine in CH2Cl2 at room temperature furnished cleanly and rapidly the desired 
electrophilic species 4, which upon reaction with 3,4,5-trimethoxyphenylzinc chloride in the presence of a catalytic 
amount of PdCl2(PPh3)2 (5 mol%) provided the target olefin 1a in a quantitative yield. This result clearly indicated that 
the two steps iododestannylation-Negishi sequence was more efficient than the direct Stille coupling of 3. 
 
SCHEME 2 
 
According to this two steps sequence (iodolysis/Negishi coupling) depicted in Scheme 2, the synthesis of other targets 
triarylolefins 1b-h was envisioned from the hydrostannation of unsymmetrical diarylalkynes. In previous studies, we 
have reported that in the case of ortho substituted diarylalkynes, the ortho substituent, regardless of its electronic nature, 
directed the tributyltin addition to afford a single -vinylstannane. We opted to use this ortho-directing effect 
(ODE)[52,53] concept to prepare the hybrids 1b-h according to the retrosynthetic pathway depicted in Scheme 3. To 
control the regioselectivity of the hydrostannation reaction, we needed first to prepare diarylalkynes 5 bearing an ortho 
substituent able to exclusively directed the H-Sn bond addition across the triple bond, and therefore to provide a single 
vinyl stannane. To this end we have choosen as ortho-directing group (oDG) a bromine atom, as this substituent would 
be easy to introduce but also easy to remove at the end of the synthesis by metal-halogen exchange reaction followed by 
hydrolysis. 
 
SCHEME 3 
 
Diarylalkynes 5a-d bearing an ortho bromine atom were prepared according to Scheme 4. 5a was synthesized from 
terminal alkyne 6a by Sonogashira-Linstrumelle (S-L) coupling with 3-bromo-4-iodoanisole, readily obtained by 
regioselective iodination of 3-bromoanisole (94%). For the preparation of diarylalkynes 5b-d, the synthetic route 
involves the bromination of 3,4,5-trimethoxy-iodobenzene with molecular Br2 or MPHT[54] to provide 7 followed by 
sequential S-L coupling reactions. 
 
SCHEME 4 
The palladium-catalyzed hydrostannation reaction was next applied to ortho substituted diarylalkynes 5a-d (Scheme 5). 
As expected, a total regiochemical control was achieved by the presence of ortho bromine atom substituent. The 
reaction provide exclusively -vinylstannanes 8a-d where the Bu3Sn group is proximal to the ortho substituted aryl 
nucleus. 
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SCHEME 5 
 
Further iodolysis of 8a-d was achieved as described for 3 and vinyl iodides 9a-d were isolated in excellent yields (70-
99%) as pure (E)-isomers. For the Negishi cross coupling reaction, organozinc species were generated by 
transmetallation from Grignard reagents at 0 °C using ZnCl2 except for the synthesis of 10f. 
In this case, the organozinc species was generated after lithiation of 2-fluoro-4-iodoanisole followed by transmetalation 
with ZnCl2 as above. As shown in Scheme 5, all organozinc reagents were successfully coupled with the vinyl iodides 
9a-d in good yields (50-99%). Finally, removal of the ortho-bromo directing group was achieved by halogen-metal 
exchange reaction using n-butyllithium followed by quenching with aqueous HCl. Subsequent MOM- or TBDMS-ether 
cleavage furnished the expected triarylolefins 1b-h as pure isomers.  
The cytotoxic activity of 12 newly synthesized triaryl olefins against human colon carcinoma cell-line (HCT-116) was 
firstly evaluated using isoCA-4[33] and CA-4[55] as reference compounds. The IC50 values corresponding to the 
concentration of studied compounds leading to 50% decrease in HCT-116 cell growth are presented in Table 1.  
Newly synthesized ortho-brominated analogues 10 were not cytotoxic. As it can be observed, most of the triarylolefins 
1 retained a light cancer cell growth-inhibitory activity at a micromolar range. In particular, best inhibition results were 
obtained with hybrids 1e-h bearing the greatest resemblance to CA-4 and isoCA-4. However, the cytotoxicities of these 
triarylolefins are not comparable with those of CA-4 and isoCA-4, even though all derivatives of type 1 carry a CA-4 
and a isoCA-4 (for 1h) moiety in their structure. 
These trisubstituted olefinic combretastatin analogues were next evaluated as tubulin polymerization inhibitors. All 
samples were dissolved in DMSO, incubated at 37 °C for 10 min and at 0 °C for 5 min before evaluation of the tubulin 
assembly rate.  
Triarylolefins were tested at different concentrations and the IC50 was calculated only for compounds inhibiting tubulin 
assembly by more than 50% at 9.0 x 10-6 M. The tubulin assembly assay was realized according to a slightly modified 
Guénard’s protocol.[56] The tested analogues show a moderate potency (micromolar level) related to the references 
compounds CA-4 and isoCA-4. When comparing the inhibition of tubulin polymerization versus the cell growth 
inhibitory effect, we do not find a good correlation for most of the active compounds except for the hybrid 1h. This 
hybrid most closely resembling CA-4 and isoCA-4 in structure displayed a potent anti-mitotic activity and a weak 
cytotoxicity. 
 
TABLE 1 
 
3. Conclusion 
The aim of this work was to devise a synthetic strategy to prepare stereodefined triarylolefins 1 as CA-4 and isoCA-4 
hybrids and to evaluate the influence of the double bond substitution on antitumor activity. From a chemical 
perspective, the “traceless use” of an ortho bromo substituent to regioselectively control the addition of tributyltin 
hydride on internal alkynes leading to stannylated stilbenes precursors of trisubstituted olefins 1 is notable. The new 
CA-4 and isoCA-4 analogues were evaluated for their cell growth inhibition and antitubulin activity. Some of these 
compounds showed interesting antitubulin activities (8 M) but are less cytotoxic than CA-4 and isoCA-4, indicating 
that the nature of the olefin substitution in combretastatin series plays an important role on activity. 
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4. Experimental 
4.1 General Considerations 
Tetrahydrofuran (THF) and diethylether were distilled from sodium-benzophenone ketyl. Piperidine, and triethylamine were distilled 
from potassium hydroxide under argon prior to use. The compounds were all identified by usual physical methods, i.e. 1H-NMR, 13C-
NMR, IR, MS and elemental analysis. 1H and 13C NMR spectra were measured in CDCl3 with a Bruker Avance 300. 1H chemical 
shifts are reported in ppm from an internal standard TMS or of residual chloroform (7.27 ppm). The following abreviation are used: 
m (multiplet), s (singlet), bs (broad singlet), d (doublet). 13C chemical shifts are reported in ppm from the central peak of 
deuteriochloroform (77.14). IR spectra were measured on a Bruker Vector 22 spectrophotometer (neat, cm-1). Elemental analyses 
were performed with a Perkin-Elmer 240 analyser. Mass spectra were obtained with a LCT Micromass spectrometer. Analytical TLC 
was performed on Merck precoated silica gel 60F plates. Merck silica gel 60 (230-400 mesh) was used for column chromatography.  
 
3-Bromo-4-iodoanisole  
A stirred solution of 3-bromoanisole (500 mg, 2.15 mmol), HgO (354 mg, 1.63 mmol), Ac2O (0.1 mL) in CH2Cl2 (10 mL) was 
refluxed for 30 min. Then, I2 (709 mg, 2.79 mmol) was added by 6 portions every 30 min. After refluxing for 12 h and filtration over 
a pad of celite, the filtrate was washed with a saturated Na2S2O3 solution. The aqueous layer was extracted with CH2Cl2 (3 x 10 mL) 
and the combined organic layers were dried with MgSO4 and evaporated to dryness. Purification by flash chromatography 
(cyclohexane) afforded the titled compound  
Yield: 94 %. TLC: Rf 0.68 (cyclohexane/Et2O: 95/5). IR (neat) νmax/ cm-1: 2933, 2831, 2361, 2183, 2013, 1579, 1556, 1463, 1436, 
1384, 1285, 1260, 1225, 1182, 1093, 1034, 1001. 1H NMR (300 MHz, CDCl3) δ ppm 7.68 (d, J=8.8 Hz, 1H), 7.19 (d, J=2.8 Hz, 1H), 
6.59 (dd, J=2.8 Hz, J=8.8 Hz, 1H), 3.77 (s, 3H). 
 
2-Bromo-1-iodo-3,4,5-trimethoxybenzene (7) 
Br2 (192 mg) was slowly added to a solution of 1-iodo-3,4,5-trimethoxybenzene (1.47 g; 5 mmol) in AcOH (10 mL) and the mixture 
was stirred over night. After neutralization with NaOH (1N), the reaction product was extracted with EtOAc (3 x 10 mL). The 
organic solutions were dried with MgSO4 and evaporated to dryness. Purification by flash chromatography (cyclohexane/EtOAc: 9/1) 
afforded the titled compound. 
Yield: 92 %. TLC: Rf 0.68 (cyclohexane/EtOAc: 8/2). IR (neat) νmax/cm-1: 2935, 1562, 1472, 1421, 1371, 1297, 1233, 1102, 1003. 
1H NMR (300 MHz, CDCl3) δ ppm 7.26 (m, 1H), 7.19 (s, 1H), 3.87 (s, 3H), 3.87 (s, 3H), 3.84 (s, 3H). 
 
1-Ethynyl-3,4,5-trimethoxybenzene (6a) 
To a stirred solution of iodo-3,4,5-trimethoxybenzene (10 mmol) in piperidine (15 mL) was added, CuI (190 mg, 1 mmol), 
PdCl2(PPh3)2  (351 mg, 0.5 mmol) and trimethylsilylacetylene (15 mmol). The stirred mixture was kept for a night at room 
temperature and was then treated with HCl 10 % (20 mL). After extraction with CH2Cl2 (3 x 15 mL), the organic layers were dried 
with MgSO4 and evaporated to dryness. Next, the crude mixture was diluted in MeOH (15 mL) containing K2CO3 (15 mmol). After 
stirring for 1 h at room temperature, the black mixture was concentrated under vacuum and treated with a diluted HCl solution until 
pH = 6. The aqueous layer was extracted with CH2Cl2 (3 x 30 mL) and the combined organic layers were dried with MgSO4 and 
evaporated to dryness. Purification by flash chromatography afforded 6a. 
Yield: 82 %. TLC: Rf 0.47 (cyclohexane/EtOAc: 8/2). IR (neat) νmax/cm-1: 3242, 2989, 2939, 2023, 1967, 1576, 1501, 1450, 1427, 
1410, 1329, 1232, 1180, 1125, 1034, 998, 955, 832, 773. 1H NMR (300 MHz, CDCl3) δ ppm 6.72 (s, 2H), 3.85 (s, 6H), 3.83 (s, 3H), 
3.02 (s, 1H). 13C NMR (75 MHz, CDCl3) δ ppm 153.1 (2C), 123.68, 117.05, 114.99, 109.35 (2C), 105.21, 83.73, 76.26, 60.99, 56.17 
(2C). MS (APCI) m/z: 193.22 (M+H)+. 
 
Synthesis of 2-Bromo-1-ethynyl-3,4,5-trimethoxybenzene (6b) 
To a stirred solution of 7 (10 mmol) in THF (15 mL) and Et3N (15 mL) was added, CuI (190 mg, 1 mmol), PdCl2(PPh3)2  (351 mg, 
0.5 mmol) and trimethylsilylacetylene (15 mmol). The stirred mixture was kept for a night at room temperature and was then treated 
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with HCl 10 % (20 mL). After extraction with CH2Cl2 (3 x 15 mL), the organic layers were dried with MgSO4 and evaporated to 
dryness. Next, the crude mixture was diluted in MeOH (15 mL) containing K2CO3 (20 mmol). After stirring for 1 h at room 
temperature, the black mixture was concentrated under vacuum and treated with a diluted HCl solution until pH = 6. The aqueous 
layer was extracted with CH2Cl2 (3 x 30 mL) and the combined organic layers were dried with MgSO4 and evaporated to dryness. 
Purification by flash chromatography afforded 6b. 
Yield: 72%. TLC: Rf 0.17 (cyclohexane/EtOAc: 95/5). IR (neat) νmax/ cm-1: 3291, 2938, 1555, 1477, 1424, 1383, 1336, 1241, 1195, 
1166, 1105, 1041, 1004. 1H NMR (300 MHz, CDCl3) δ ppm 6.73 (s, 1H), 3.75 (s, 3H), 3.73 (s, 3H) , 3.70 (s, 3H), 3.17 (s, 1H). 13C 
NMR (75 MHz, CDCl3) δ ppm 155.2, 152.6, 119.3, 112.9, 112.6, 80.9, 61.3, 61.0, 56.2 (two C missing). 
 
Synthesis of internal alkynes 5 
To a mixture of required aryl iodide (0.7 mmol), PdCl2(PPh3)2 (0.1 mmol), CuI (0.15 mmol), TEA (10 mL) in THF (10 mL) was 
added dropwise under an argon atmosphere, a solution of 6a or 6b (1.0 mmol). The mixture was stirred at 60°C for a night. Then 
Et2O (20 mL) was added to the crude and the mixture was filtered over a short pad of celite. The organic layer was washed with brine 
(5 mL) twice, separated, dried over MgSO4, filtered, and concentrated. Purification by flash chromatography afforded internal 
alkynes 5a-d. 
 
5-(2-(2-Bromo-4-methoxyphenyl)ethynyl)-1,2,3-trimethoxybenzene (5a) 
Yield: 80 %. Anal. calcd for 5a (C18H17BrO4): C, 57.31; H, 4.54. Found: C, 57.18; H, 4.39. TLC: Rf 0.14 (cyclohexane/EtOAc: 9/1). 
IR (neat) νmax/ cm-1: 3751, 2935, 1601, 1572, 1506, 1457, 1437, 1409, 1351, 1287, 1268, 1221, 1182, 1123, 1027. 1H NMR (300 
MHz, CDCl3) δ ppm 7.45 (d, J=8.6 Hz, 1H), 7.15 (d, J=2.5 Hz, 1H), 6.83 (dd, J = 2.6 Hz, J = 8.7 Hz, 1H), 6.78 (s, 2H), 3.87 (s, 6H), 
3.86 (s, 3H), 3.80 (s, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 159.9, 153.2, 138.9, 133.9, 126.3, 118.3, 117.9, 117.5, 113.6, 108.8, 
92.3, 87.1, 61.0, 56.2, 55.7.MS (APCI) m/z: 377.0 ((M+H)+, 79Br ), 379.0 ((M+H)+, 81Br). 
 
2-Bromo-3,4,5-trimethoxy-1-(2-(4-methoxyphenyl) ethynyl)benzene (5b) 
Yield: 86 %. Anal. calcd for 5b (C18H17BrO4): C, 57.31; H, 4.54. Found: C, 57.11; H, 4.35. TLC: Rf 0.30 (cyclohexane/Et2O: 9/1). 
IR (neat) νmax/ cm-1: 2936, 2218, 1736, 1604, 1578, 1551, 1511, 1477, 1462, 1427, 1383, 1358, 1295, 1250, 1174, 1098, 1030. 1H 
NMR (300 MHz, CDCl3) δ ppm 7.51 (d, J = 8.3 Hz, 2H), 6.90 (s, 2H), 6.89 (d, J = 10.2 Hz, 2H), 3.90 (s, 6H), 3.87 (s, 3H), 3.83 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ ppm 159.9, 152.6, 151.3, 143.7, 133.2, 120.9, 115.1, 114.1, 112.6, 111.6, 93.2, 86.9, 61.3, 61.1, 
56.3, 55.4. MS (APCI) m/z: 377.0 ((M+H)+, 79Br ), 379.0 ((M+H)+, 81Br). 
 
(5-(2-(2-Bromo-3,4,5-trimethoxyphenyl)ethynyl)-2-methoxyphen-oxy)(tert-butyl)dimethylsilane (5c) 
Yield: 66 %. TLC: Rf 0.35 (cyclohexane/EtOAc: 9/1). IR (neat) νmax/ cm-1: 2931, 2855, 2211, 1566, 1508, 1477, 1443, 1413, 1384, 
1360, 1288, 1257, 1233, 1189, 1151, 1132, 1107, 1043, 1023. 1H NMR (300 MHz, CDCl3) δ ppm 7.00 (dd, J = 1.9 Hz, J = 8.3 Hz, 
1H), 6.88 (d, J = 1.7 Hz, 1H), 6.73 (s, 1H), 6.64 (d, J = 8.4 Hz, 1H), 3.74 (s, 3H), 3.73 (s, 3H), 3.70 (s, 3H), 3.66 (s, 3H), 0.83 (s, 
9H), 0.00 (s, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 152.6, 151.9, 151.3, 144.8, 143.6, 125.9, 123.9, 120.8, 115.1, 112.6, 111.7, 
111.5, 93.2, 86.5, 61.2, 60.9, 56.2, 55.4, 25.7 (3C), 18.5, -4.6 (2C). MS (APCI) m/z: 509.1 (M+H)+. Anal. calcd for 5c 
(C24H31BrO5Si): C, 56.80; H, 6.16. Found: C, 56.65; H, 6.05. 
 
4-(2-(2-Bromo-3,4,5-trimethoxyphenyl)ethynyl)-1-methoxy-2-(methoxymethoxy)benzene (5d) 
Yield: 80 %. Anal. calcd for 5d (C20H21BrO6): C, 54.93; H, 4.84. Found: C, 54.83; H, 4.80. TLC: Rf 0.20 (cyclohexane/EtOAc: 9/1). 
IR (neat) νmax/ cm-1: 2942, 1556, 1514, 1478, 1421, 1382, 1364, 1317, 1246, 1198, 1151, 1131, 1104, 1074, 1047. 1H NMR (300 
MHz, CDCl3) δ ppm 7.28 (d, J = 1.9 Hz, 1H) , 7.17 (dd, J = 2.3 Hz, J = 8.8 Hz, 1H), 6.84 (s, 1H) , 6.80 (d, J = 8.4 Hz, 1H), 5.18 (s, 
2H), 3.84 (s, 6H), 3.83 (s, 3H), 3.80 (s, 3H), 3.47 (s, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 152.6, 151.3, 150.5, 146.2, 143.7, 
126.6, 120.7, 119.3, 115.3, 112.6, 111.7, 95.5, 93.0, 86.7, 61.3, 60.9, 56.3, 56.2, 55.9. MS (APCI) m/z: 437.28 ((M+H)+, 79Br ), 439.0 
((M+H)+, 81Br). 
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General Procedure for the hydrostannation of diarylalkynes. 
Tributyltin hydride (12 mmol) was added dropwise at room temperature to a solution of PdCl2(PPh3)2 (0.1 mmol) and alkyne (10 
mmol) in THF (15 mL). The dark brown reaction mixture was stirred for 90 minutes. Then, the solution was concentrated in vacuo. 
Purification by flash chromatography on silica gel gave the desired products 3 and 8a-d. 
 
(E)-(1,2-bis(4-Methoxyphenyl)vinyl)tributylstannane (3). 
Yield: 79 %. TLC: Rf 0.82 (cyclohexane/Et2O: 95/5). IR (neat) νmax/ cm-1: 2954, 2920, 2361, 2162, 1965, 1604, 1503, 1462, 1376, 
1279, 1242, 1173, 1106, 1071, 1038. 1H NMR (300 MHz, CDCl3) δ 6.87 (d, J = 8.7 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 6.73 (d, J = 
8.7 Hz, 2H), 6.55 (d, J = 8.7 Hz, 2H), 6.48 (s, 1H), 3.68 (s, 3H), 3.60 (s, 3H), 1.45-1.35 (m, 6H), 1.29-1.15 (m, 6H), 0.92-0.76 (m, 
5H). 13C NMR (75 MHz, CDCl3) δ 158.1, 157.2, 146.8, 138.1, 137.8, 130.6, 130.4 (2C), 127.5 (2C), 114.1 (2C), 113.3 (2C), 55.2, 
55.1, 30.6 (3C), 29.0 (3C), 27.5 (3C), 13.7 (3C). 
 
(E)-(1-(2-Bromo-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl) vinyl)tributylstannane (8a) 
Yield: 78 %. TLC: Rf 0.29 (cyclohexane/EtOAc: 9/1). 1H NMR (300 MHz, CDCl3) δ ppm 7.17 (d, J = 2.2 Hz, 1H), 6.87 (d, J = 8.4 
Hz, 1H), 6.82 (dd, J = 2.2 Hz, J = 8.4 Hz, 1H), 6.57 (s, 1H), 6.26 (s, 2H), 3.78 (s, 6H), 3.59 (s, 6H), 1.49 (m, 6H), 1.29 (m, 6H), 0.95 
(m, 6H), 0. 87 (m, 9H). 13C NMR (75 MHz, CDCl3) δ ppm 158.0, 152.8 (2C), 148.9, 139.1, 138.7, 137.2, 133.2, 128.4, 121.7, 117.7, 
114.5, 106.0, 60.9, 55.8 (3C), 28.9 (3C), 27.5 (3C), 13.8 (3C), 10.9 (3C). 
 
(E)-(1-(2-Bromo-3,4,5-trimethoxyphenyl)-2-(4-methoxyphenyl) vinyl)tributylstannane (8b) 
Yield: 92 %. TLC: Rf 0. 2 (cyclohexane/Et2O: 95/5). IR (neat) νmax/ cm-1: 2928, 2847, 2168, 2029, 1973, 1604, 1554, 1508, 1476, 
1420, 1378, 1319, 1286, 1248, 1175, 1161, 1106. 1H NMR (300 MHz, CDCl3) δ ppm 6.95 (d, J = 8.7 Hz, 2H), 6.68 (d, J = 8.7 Hz, 
2H), 6.57 (s, 1H), 6.31 (s, 1H), 3.91 (s, 6H), 3.74 (s, 3H), 3.73 (s, 3H), 1.52-1.43 (m, 6H), 1.35-1.23 (m, 6H), 0.98-0.93 (m, 6H), 0.87 
(t, J = 7.3 Hz, 9H). 13C NMR (75 MHz, CDCl3) δ ppm 158.4, 153.1, 151.2, 146.5, 142.0, 140.4, 137.9, 130.2, 129.9 (2C), 113.4 (2C), 
107.2, 105.9, 61.3, 60.9, 55.9, 55.1, 28.9 (3C), 27.3 (3C), 13.7 (3C), 10.8 (3C). MS (APCI) m/z: 669.0 (M+H)+. 
 
(E)-(5-(2-(2-Bromo-3,4,5-trimethoxyphenyl)-2-(tributylstannyl) vinyl)-2-methoxyphenoxy)(tert-butyl)dimethyl silane (8c) 
Yield: 75 %. TLC: Rf 0.58 (cyclohexane/EtOAc: 9/1). IR (neat) νmax/ cm-1: 3836, 2929, 2854, 1556, 1506, 1463, 1423, 1380, 1281, 
1231, 1139, 1109, 1013. 1H NMR (300 MHz, CDCl3) δ ppm 7.00 (dd, J = 1.9 Hz, J = 8.3 Hz, 1H) , 6.88 (d, J = 1.7 Hz, 1H) , 6.73 (s, 
1H) , 6.64 (d, J = 8.4 Hz, 1H), 3.74 (s, 3H) , 3.73 (s, 3H) , 3.70 (s, 3H), 3.66 (s, 3H) , 0.83 (s, 9H) , 0.00 (s, 6H). 13C NMR (75 MHz, 
CDCl3) δ ppm 152.5, 151.5, 149.7, 146.2, 144.6, 142.8, 142.3, 138.9, 127.9, 123.3, 120.1, 111.2, 107.3, 61.3, 60.6, 56.4, 55.4, 29 .1 
(3C), 27.5 (3C), 25.9 (3C), 18.6, 13.5 (3C), 8.07 (3C), -2.7 (2C). 
 
(E)-(1-(2-Bromo-3,4,5-trimethoxyphenyl)-2-(4-methoxy-3-(methoxymethoxy)phenyl)vinyl)tributyl stannane (8d) 
Yield: 75 %. TLC: Rf 0.28 (cyclohexane/EtOAc: 9/1). IR (neat) νmax/ cm-1: 2916, 1737, 1373, 1234, 1044. 1H NMR (300 MHz, 
CDCl3) δ ppm 6.76 (s, 1H), 6.64 (s, 2H), 6.47 (s, 1H), 6.25 (s, 1H), 4.85 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.72 (s, 3H), 3.65 (s, 3H), 
3.27 (s, 3H), 1.45-1.36 (m, 6H), 1.27-1.15 (m, 6H), 0.91-0.85 (m, 6H), 0.79 (t, J = 7.2 Hz, 9H). 13C NMR (75 MHz, CDCl3) δ ppm 
153.1, 151.2, 148.7, 147.1, 145.8, 141.8, 140.4, 137.7, 130.5, 123.4, 116.1, 111.0, 107.0, 105.8, 95.1, 60.9, 60.7, 55.9, 55.6, 28.8 
(3C), 27.2 (3C), 13.5 (3C), 10.8 (3C). 
 
General Procedure for the iodination of 3 and 8a-d . 
To a CH2Cl2 (15 mL) solution containing vinyl stannane (0.39 mmol) was added in one portion I2 (0.39 mmol) at 0°C. The mixture 
was then stirred at rt until the disappearance of the starting material (judged by TLC). Then a saturated Na2S2O3 solution (10 mL) 
was added to the mixture which was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried with MgSO4 and 
evaporated to dryness. Purification by flash chromatography afforded terminal alkynes 4 and 9a-d. 
 
(E)-1-Iodo-1,2-bis(4-methoxyphenyl)ethene (4) 
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Yield: 74 %. Anal. calcd for 4 (C16H15IO2): C, 52.48; H, 4.13. Found: C, 52.24; H, 4.07. TLC: Rf 0.68 (cyclohexane/EtOAc: 8/2). IR 
(neat) νmax/cm-1: 2932, 2938, 1596, 1568, 1504, 1462, 1440, 1421, 1286, 1245, 1174, 1161, 1109, 1024. 1H NMR (300 MHz, CDCl3) 
δ ppm 7.22 (s, 1H), 7.18 (d, J = 8.7 Hz, 2H), 6.80 (d, J = 8.9 Hz, 2H), 6.74 (d, J = 8.7 Hz, 2H), 6.57 (d, J = 8.9 Hz, 2H), 3.73 (s, 3H), 
3.65 (m, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 159.3, 158.8, 140.3, 135.6, 130.2 (2C), 130.1, 129.9 (2C), 114.0 (2C), 113.5 (2C), 
96.1, 55.3, 55.2. MS (CI) m/z: 365.9 (M+H+).  
 
(E)-2-Bromo-1-(1-iodo-2-(3,4,5-trimethoxyphenyl)vinyl)-4-methoxy benzene (9) 
Yield: 70 %. Anal. calcd for 9a (C18H18BrIO4): C, 42.80; H, 3.59. Found: C, 42.74; H, 3.57. TLC: Rf 0.13 (cyclohexane/EtOAc: 9/1). 
1H NMR (300 MHz, CDCl3) δ ppm 7.32 (s, 1H), 7.19 (d, J= 8.5 Hz, 1H), 7.15 (d, J = 2.6 Hz, 1H), 6.86 (dd, J = 8.5 Hz, J = 2.6 Hz, 
1H), 6.14 (s, 2H), 3.78 (s, 3H), 3.77 (s, 3H), 3.57 (s, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 160.0, 152.9, 142.8, 137.8, 135.9, 
132.2, 130.7, 123.2 118.4, 114.4, 105.4 (2C), 94.5, 60.8, 55.8, 55.7 (2C). MS (APCI) m/z: 500.0 (M+H+).  
 
(E)-1-(2-(2-Bromo-3,4,5-trimethoxyphenyl)-2-iodovinyl)-4-methoxy benzene (9b) 
Yield: 85 %. Anal. calcd for 9b (C18H18BrIO4): C, 42.80; H, 3.59. Found: C, 42.59; H, 3.37. TLC: Rf 0.21 (cyclohexane/EtOAc: 
95/5). 1H NMR (300 MHz, CDCl3) δ ppm 7,31 (s, 1H,), 6,81 (d, J = 8.7 Hz, 2H), 6,65 (d, J = 8.7 Hz, 2H), 6,62 (s, 1H), 3,93 (s, 3H), 
3,91 (s, 3H), 3,79 (s, 3H), 3,74 (s, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 159.5, 151.9, 145.6, 138.8, 136.0, 133.6, 130.3 (2C), 
128.6, 113.5 (2C), 107.2, 106.5, 90.7, 60.93, 60.6, 56.1, 55.4. MS (ESI) m/z: 528.8 (M+Na+). 
 
(E)-(5-(2-(2-Bromo-3,4,5-trimethoxyphenyl)-2-iodovinyl)-2-methoxy phenoxy)(tert-butyl)dimethyl silane (9c) 
Yield: 99 %. TLC: Rf 0.50 (cyclohexane/EtOAc: 9/1). 1H NMR (300 MHz, CDCl3) δ ppm 7,26 (s, 1H), 6,67 (d, J = 8.4 Hz, 1H), 
6,62 (s, 1H), 6,56 (dd, J = 8.4 Hz, J = 2.2 Hz, 1H), 6,36 (d, J = 2.2 Hz, 1H), 3,91 (s, 3H), 3,80 (s, 3H), 3,78 (s, 3H), 3,74 (s, 3H), 0,99 
(s, 9H), 0,15 (s, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 153.3, 151.8, 151.14, 144.6, 143.1, 142.1, 138.7, 129.7, 123.1, 119.9, 111.3, 
109.0, 107.9, 92.2, 61.2, 61.1, 56.1, 55.3, 25.6 (3C), 16.4, -4.8 (2C). MS (ESI) m/z: 659,0 (M+Na+). Anal. calcd for 9c 
(C24H32BrIO5Si): C, 45.37; H, 5.08. Found: C, 45.17; H, 4.98. 
 
(E)-2-Bromo-1-(1-iodo-2-(4-methoxy-3-(methoxymethoxy)phenyl) vinyl)-3,4,5-trimethoxybenzene (9d) 
Yield: 88 %. TLC: Rf 0.49 (cyclohexane/EtOAc: 8/2). IR (neat) νmax/ cm-1: 2984, 1737, 1373, 134, 1044. 1H NMR (300 MHz, 
CDCl3) δ ppm 7.27 (s, 1H), 6.72-6.61 (m, 3H), 6.63 (s, 1H), 4.92 (s, 2H), 3.92 (s, 6H), 3.82 (s, 3H), 3.80 (s, 3H), 3.34 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ ppm 153.4, 151.8, 149.4, 146.1, 143.1, 141.9, 138.5, 129.7, 123.4, 115.2, 110.9, 108.8, 107.8, 95.2, 92.6, 
61.1, 61.0, 56.2, 55.8 (2C). Anal. calcd for 9d (C20H22BrIO6): C, 42.50; H, 3.92. Found: C, 42.38; H, 3.88. 
 
General procedure for the PdCl2(PPh3)-catalyzed cross coupling reaction of vinyl iodides with arylzinc reagents. 
To a solution of vinyl iodides 4 or 9a-d, PdCl2(PPh3)2 (5 mol%) in THF was added at room temperature, ArZnCl (2 equiv.) prepared 
by transmetallation from the corresponding Grignard reagent (2.2 equiv.) and anhydrous ZnCl2 (3 equiv.). The reaction was stirred at 
room temperature and monitored by TLC until complete consumption of starting materials. The reaction was hydrolyzed at 0°C with 
aqueous HCl (1N), extracted with Et2O, the organic extract was dried over MgSO4 and the solvent was removed in vacuo. 
Purification by flash chromatography afforded olefins 1a, 10a-g. 
 
(E)-5-(1,2-bis(4-Methoxyphenyl)vinyl)-1,2,3-trimethoxybenzene (1a) 
Yield: 99 %. Anal. calcd for 1a (C25H26O5): C, 73.87; H, 6.45. Found: C, 73.77; H, 6.38. TLC: Rf 0.31 (cyclohexane/EtOAc: 8/2). IR 
(neat) νmax/cm-1: 2930, 1603, 1576, 1507, 1463, 1412, 1332, 1285, 1238, 1173, 1119, 1028. 1H NMR (300 MHz, CDCl3) δ ppm 7.13 
(d, J = 8.7 Hz, 2H), 6.99 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.81 (s, 1H), 6.69 (d, J = 8.8 Hz, 2H), 6.53 (s, 2H), 3.86 (s, 
3H), 3.85 (s, 3H), 3.79 (s, 6H), 3.76 (s, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 158.9, 158.3, 152.8 (2C), 140.4, 139.9, 137.6, 132.5, 
131.7 (2C), 130.7 (2C), 130.2, 126.9, 113.9 (2C), 113.4 (2C), 104.9 (2C), 60.9, 56.1 (3C), 55.2. MS (CI) m/z: 407.2 (M+H+). 
 
(Z)-5-(1-(2-bromo-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl) vinyl)-1,2,3-trimethoxybenzene (10a) 
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Yield: 95 %. Anal. calcd for 10a (C27H29BrO7): C, 59.46; H, 5.36. Found: C, 59.29; H, 5.24. TLC: Rf 0.13 (cyclohexane/EtOAc: 
8/2). IR (neat) νmax/ cm-1: 2936, 2836, 1578, 1506, 1452, 1418, 1334, 1283, 1229, 1186, 1122, 1032, 1004. 1H NMR (300 MHz, 
CDCl3) δ ppm 7.23 (d, J = 2.5 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 6.91 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 6.71 (s, 1H), 6.54 (s, 2H), 
6.26 (s, 2H), 3.92 (s, 3H), 3.81 (s, 3H), 3.80 (s, 6H), 3.79 (s, 6H), 3.60 (s, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 159.6, 153.4 (2C), 
153.0 (2C), 152.8, 139.9, 137.6, 137.3, 133.1, 132.5, 132.3, 128.7, 124.9, 118.7, 114.2, 106.2 (2H), 104.0 (2C), 60.9, 60.8, 56.3, 56.1 
(2C), 55.6 (2C). MS (APCI) m/z: 547.0 (M+H+).  
 
(Z)-1-(1-(2-Bromo-3,4,5-trimethoxyphenyl)-2-(4-methoxyphenyl) vinyl)-4-methoxybenzene (10b) 
Yield: 99 %. Anal. calcd for 10b (C25H25BrO5): C, 61.86; H, 5.19. Found: C, 61.65; H, 5.04. TLC: Rf 0.41 (cyclohexane/EtOAc: 
8/2). 1H NMR (300 MHz, CDCl3) δ ppm 7.20 (d, J = 8.4 Hz, 2H), 6.90 (s, 1H), 6.82 (d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.7 Hz, 2H), 
6.61 (d, J = 8.4 Hz, 2H), 6.48 (s, 1H), 3.96 (s, 3H) , 3.92 (s, 3H), 3.81 (s, 3H), 3.75 (s, 3H), 3.72 (s, 3H).  13C NMR (75 MHz, CDCl3) 
δ ppm 159.0, 158.5, 153.4, 151.8, 142.5, 138.2, 136.9, 134.0, 130.1 (2C), 129.8, 127.5 (2C), 126.8, 113.8 (2C), 113.6 (2C), 110.8, 
110.2, 61.4, 61.2, 56.2, 55.3, 55.2. MS (ESI) m/z: 485.2 (M+H+). 
 
(Z)-(5-(2-(2-Bromo-3,4,5-trimethoxyphenyl)-2-(4-methoxyphenyl) vinyl)-2-methoxyphenoxy)(tert-butyl)dimethyl silane (10c) 
Yield: 77 %. Anal. calcd for 10c (C31H39BrO6Si): C, 60.48; H, 6.39. Found: C, 60.32; H, 6.30. TLC: Rf 0.14 (cyclohexane/EtOAc: 
9/1). IR (neat) νmax/ cm-1: 2203, 2149, 2073, 2020, 1985, 1605, 1570, 1497, 1440, 1388, 1275, 1243, 1178, 1136, 1109, 1040, 1012. 
1H NMR (300 MHz, CDCl3) δ ppm 7.22 (d, J = 7.9 Hz, 2H), 6.88 (s, 1H), 6.84 (d, J = 7.9 Hz, 2H), 6.67 (s, 2H), 6.56 (s, 1H), 6.49 (s, 
1H), 3.95 (s, 3H), 3.91 (s, 3H), 3.80 (s, 3H), 3.75 (s, 3H), 3.72 (s, 3H), 0.92 (s, 9H), 0.03 (s, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 
158.9, 153.3, 151.8, 150.3, 144.4, 142.4, 138.1, 136.8, 134.1, 130.0, 127.5 (2C), 126.9, 123.6, 120.8, 113.8 (2C), 111.4, 110.7, 110.0, 
61.2, 61.1, 56.1, 55.3, 55.3, 25.6 (3C), 18.3, -6.1 (2C). MS (APCI) m/z: 617.1 (M+H+).  
 
(Z)-2-bromo-3,4,5-trimethoxy-1-(2-(4-methoxy-3-(methoxymethoxy) phenyl)-1-p-tolylvinyl)benzene (10d) 
Yield: 72 %. TLC: Rf 0.50 (cyclohexane/EtOAc: 7/3). IR (neat) νmax/ cm-1: 2190, 1512, 1263, 1106, 1008. 1H NMR (300 MHz, 
CDCl3) δ ppm 7.22 (d, J = 8.3 Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 6.99 (s, 1H), 6.80 (d, J = 1.6 Hz, 1H), 6.76 (t, J = 5.2 Hz, 1H), 6.73 
(d, J = 8.4 Hz, 1H), 6.58 (s, 1H), 4.95 (s, 2H), 3.95 (s, 3H), 3.92 (s, 3H), 3.83 (s, 3H), 3.74 (s, 3H), 3.38 (s, 3H), 2.04 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ ppm 153.5, 151.8, 148.8, 145.9, 142.4, 138.7, 138.3, 137.1, 136.6, 130.0 (2C), 129.1, 127.5 (2C), 126.2, 
124.1, 116.1, 111.1, 110.6, 110.1, 95.2, 61.1, 61.0, 56.2, 55.9, 55.8. MS (APCI) m/z: 551.0 (M+Na+, 79Br), 553.1 (M+Na+, 81Br). 
Anal. calcd for 10d (C27H29BrO6): C, 61.25; H, 5.52. Found: C, 61.31; H, 5.52. 
 
(Z)-2-(1-(2-Bromo-3,4,5-trimethoxyphenyl)-2-(4-methoxy-3-(methoxymethoxy)phenyl)vinyl) naphthalene (10e) 
Yield: 72 %. Anal. calcd for 10e (C30H29BrO6): C, 63.72; H, 5.17. Found: C, 63.45; H, 5.00. TLC: Rf 0.13 (cyclohexane/EtOAc: 
8/2). IR (neat) νmax/ cm-1: 2989, 1737, 1373, 1236, 1045. 1H NMR (300 MHz, CDCl3) δ ppm 7.81 (d, J = 9.2 Hz, 1H), 7.81-7.50 (m, 
2H), 7.63 (d, J = 1.8 Hz, 1H), 7.61 (dd, J = 1.9 Hz, J = 3.7 Hz, 1H), 7.44 (d, J = 9.4 Hz, 1H), 7.44 (dd, J = 1.9 Hz, J = 3.1 Hz, 1H), 
6.86 (d, J = 1.9 Hz, 1H), 6.82 (dd, J = 1.9 Hz, J = 8.5 Hz, 1H), 6.66 (s, 1H)6.76 (d, J = 8.4 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 
ppm 153.6, 151.9, 149.0, 146.0, 142.6, 138.8, 138.6, 136.4, 133.5, 132.7, 129.9, 128.9, 128.3, 127.9, 127.5, 126.1, 125.9, 125.5, 
124.4, 124.3, 116.3, 111.2, 110.8, 110.2, 95.2, 61.2, 61.1, 56.2, 55.9, 55.8. MS (APCI) m/z: 587.2 (M+Na+, 79Br), 589.1 (M+Na+, 
81Br). 
 
(Z)-2-Bromo-1-(1-(3-fluoro-4-methoxyphenyl)-2-(4-methoxy-3-(methoxymethoxy)phenyl)vinyl)-3,4,5-trimethoxybenzene (10f) 
Yield: 50 %. Anal. calcd for 10f (C27H28BrFO7): C, 57.56; H, 5.01. Found: C, 57.50; H, 4.98. TLC: Rf 0.33 (cyclohexane/EtOAc: 
7/3). IR (neat) νmax/ cm-1: 2937, 1514, 1481, 1385, 1262, 1156, 1132, 1106, 1079, 1009. 1H NMR (300 MHz, CDCl3) δ ppm 7.09-
7.03 (m, 1H), 7.02-6.98 (m, 1H), 6.92 (s, 1H), 6.87 (d, J = 8.6 Hz, 1H), 6.76 (d, J = 10.4 Hz, 1H), 6.74 (s, 1H), 6.56 (s, 1H), 4.94 (s, 
2H), 3.95 (s, 3H), 3.92 (s, 3H), 3.88 (s, 3H), 3.83 (s, 3H), 3.74 (s, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 153.6, 152.3 (1C, d, 
J=244.9 Hz), 151.9, 148.9, 146.9, 146.8, 146.0, 142.6, 137.4, 136.0, 134.8, 129.7, 127.6, 124.2, 122.2, 116.1, 113.9 (1C, d, J=19.3 
Hz), 113.1, 111.2, 110.6, 110.0, 95.2, 61.2, 61.1, 56.3, 56.2, 55.9, 55.8. MS (APCI) m/z: 441.0 (M+H+). 
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(Z)-1-(1,2-bis(4-Methoxy-3-(methoxymethoxy)phenyl)vinyl)-2-bromo-3,4,5-trimethoxybenzene (10 g) 
Yield: 54 %. Anal. calcd for 10g (C29H33BrO9): C, 57.53; H, 5.49. Found: C, 57.08; H, 5.10. TLC: Rf 0.20 (cyclohexane/EtOAc: 
7/3). IR (neat) νmax/ cm-1: 2984, 1737, 1373, 1235, 1045. 1H NMR (300 MHz, CDCl3) δ ppm 7.22 (d, J = 1.5 Hz, 1H), 6.91 (s, 1H), 
6.81 (d, J = 2.0 Hz, 2H), 6.80-6.70 (m, 3H), 6.56 (s, 1H), 5.19 (d, J = 0.9 Hz, 2H), 4.92 (s, 2H), 3.93 (s, 3H), 3.89 (s, 3H), 3.84 (s, 
3H), 3.80 (s, 3H), 3.72 (s, 3H), 3.48 (s, 3H), 3.35 (s, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 153.5, 151.8, 149.5, 148.8, 146.3, 
145.9, 142.5, 138.2, 136.5, 134.2, 129.9, 126.9, 124.1, 121.0, 116.1, 115.0, 111.5, 111.2, 110.7, 110.2, 95.9, 95.2, 61.1, 60.9, 56.2, 
56.2, 55.9, 55.8, 55.8. MS (ESI) m/z: 627.2 (M+Na+, 79Br), 629.2 (M+Na+, 81Br). 
 
Typical procedure for the synthesis of triarylolefins 1b-h 
To a cooled solution (-78°C) of 10a-g (0.25 mmol) in THF (5 mL) was added a 2.5 M hexane solution of n-BuLi (0.5 mL, 1.25 
mmol) over 2 min. After 30 min at -78°C the solution was allowed to warm to rt then HCl 1N (5 mL) was added and stirring was 
continued for 1 h. The aqueous phase was separated and extracted with EtOAc, the organic extract was dried over MgSO4 and the 
solvent was removed in vacuo. Purification by flash chromatography afforded triarylolefins 1b-h. 
 
(E)-1,2,3-Trimethoxy-5-(1-(4-methoxyphenyl)-2-(3,4,5-trimethoxy phenyl)vinyl)benzene (1b) 
Yield: 91 %. Anal. calcd for 1b (C27H30O7): C, 69.51; H, 6.48. Found: C, 69.41; H, 6.35. TLC: Rf 0.46 (cyclohexane/EtOAc: 8/2). IR 
(neat) νmax/ cm-1: 2954, 2922, 1573, 1505, 1482, 1463, 1417, 1376, 1327, 1280, 1223, 1184, 1125, 1030, 1010. 1H NMR (400 MHz, 
CDCl3) δ ppm: 7.16 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 6.71 (s, 1H), 6.55 (s, 2H), 6.29 (s, 2H), 3.93 (s, 3H), 3.86 (s, 3H), 
3.82 (s, 3H), 3.80 (s, 6H), 3.59 (s, 6H). 13C NMR (100 MHz, CDCl3) δ ppm: 159.1, 153.4, 152.9 (2C), 152.6 (2C), 141.8, 139.3, 
137.6, 132.9, 132.4, 131.7 (2C), 127.5, 114.1 (2C), 106.7 (2C), 104.9 (2C), 60.9, 56.3, 56.1 (2C), 55.7 (2C), 55.3. MS (ESI) m/z: 
467.3 (M+H+). 
 
(Z)-1-Methoxy-4-(2-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl) vinyl)benzene (1c) 
Yield: 65 %. Anal. calcd for 1c (C25H26O5): C, 73.87; H, 6.45. Found: C, 73.73; H, 6.36. TLC: Rf 0.40 (cyclohexane/EtOAc: 8/2). IR 
(neat) νmax/ cm-1: 2934, 1605, 1577, 1508, 1461, 1410, 1280, 1237, 1175, 1124, 1032. 1H NMR (300 MHz, CDCl3) δ ppm 7.28 (d, J 
= 8.8 Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 6.81 (s, 1H), 6.68 (d, J = 8.8 Hz, 2H), 6.42 (s, 2H), 3.91 (s, 3H), 
3.82 (s, 3H), 3.76 (s, 3H), 3.69 (s, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 159.1, 158.3, 153.5 (2C), 139.9, 137.3, 136.2, 135.9, 
130.8 (2C), 130.6, 128.5 (2C), 125.9, 113.6 (2C), 113.4 (2C), 107.4 (2C), 61.1, 56.1 (2C), 55.3, 55.2. MS (APCI) m/z: 407.3 
(M+H+).  
 
(Z)-2-Methoxy-5-(2-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl) vinyl)phenol (1d) 
Yield: 99 %. Anal. calcd for 1d (C25H26O6): C, 71.07; H, 5.20. Found: C, 70.95; H, 6.14. TLC: Rf 0.36 (cyclohexane/EtOAc: 8/2). IR 
(neat) νmax/ cm-1: 3335, 1561, 1411, 803. 1H NMR (300 MHz, CDCl3) δ ppm 7.12 (d, J = 8.8 Hz, 2H), 6.7 (d, J = 8.8 Hz, 2H), 6.61 
(s, 1H), 6.51 (d, J = 2 Hz, 1H), 6.47 (d, J = 8.5 Hz, 1H), 6.38 (dd, J = 8.5 Hz, J = 2 Hz, 1H), 6.27 (s, 2H), 3.76 (s, 3H), 3.68 (s, 3H), 
3.67 (s, 3H), 3.55 (s, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 159.1, 153.2 (2C), 145.4, 144.9, 140.4, 137.4, 135.9, 135.8, 131.1, 
128.5 (2C), 125.9, 121.5, 115.5, 113.6 (2C), 110.2, 107.5 (2C), 61.0, 56.1 (2C), 55.7, 55.3. MS (APCI) m/z: 423.2 (M+H+). 
 
(Z)-2-Methoxy-5-(2-p-tolyl-2-(3,4,5-trimethoxyphenyl) vinyl)phenol (1e) 
Yield: 92 %. Anal. calcd for 1e (C25H26O5): C, 73.87; H, 6.45. Found: C, 73.68; H, 6.34. TLC: Rf 0.33 (cyclohexane/EtOAc: 6/4). IR 
(neat) νmax/ cm-1: 3650, 2227, 2173, 2082, 2004, 1581, 1510, 1279, 1126. 1H NMR (300 MHz, CDCl3) δ ppm 7.17 (d, J = 9.0 Hz, 
2H), 7.05 (d, J = 8.0 Hz, 2H), 6.74 (s, 1H), 6.59 (d, J = 2.0 Hz, 1H), 6.56 (d, J = 8.4 Hz, 1H), 6.47 (dd, J = 2.0 Hz, J = 8.8 Hz, 1H), 
6.35 (s, 2H), 3.84 (s, 3H), 3.77 (s, 3H), 3.65 (m, 6H), 2.29 (s, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 153.6 (2C), 145.6, 145.1, 
140.9, 140.5, 137.4 (2C), 136.1, 131.2, 129.1 (2C), 127.4 (2C), 126.9, 121.8, 115.8, 110.3, 107.6 (2C), 61.2, 56.3 (2C), 56.0, 21.3. 
MS (APCI) m/z: 407.0 (M+H+). 
 
(Z)-2-Methoxy-5-(2-(naphthalen-2-yl)-2-(3,4,5-trimethoxyphenyl) vinyl)phenol (1f) 
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Yield: 95 %. Anal. calcd for 1f (C28H26O5): C, 76.00; H, 5.92. Found: C, 75.84; H, 5.97. TLC: Rf 0.35 (cyclohexane/EtOAc: 8/2). IR 
(neat) νmax/ cm-1: 2983, 1737, 1373, 1235, 1054. 1H NMR (300 MHz, CDCl3) δ ppm 7.81 (d, J = 9.2 Hz, 1H), 7.81-7.50 (m, 2H), 7.63 
(d, J = 1.8 Hz, 1H), 7.61 (dd, J = 1.9 Hz, J = 3.7 Hz, 1H), 7.44 (d, J = 9.4 Hz, 1H), 7.44 (dd, J= 1.9 Hz, J = 3.1 Hz, 1H), 6.86 (d, J = 
1.9 Hz, 1H), 6.82 (dd, J = 1.9 Hz, J = 8.5 Hz, 1H), 6.66 (s, 1H), 6.76 (d, J = 8.4 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ ppm 153.7 
(2C), 145.8, 145.2 (2C), 141.0, 140.8, 137.7, 135.9, 133.5, 132.9, 131.1, 128.4, 127.8, 127.7, 126.6, 126.3, 126.0, 125.6, 121.9, 
115.8, 110.3, 107.7 (2C), 61.3, 56.3 (2C), 56.0. 
 
(E)-5-(2-(3-Fluoro-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl) vinyl)-2-methoxyphenol (1g) 
Yield: 53 %. Anal. calcd for 1g (C25H25FO6): C, 68.17; H, 5.72. Found: C, 68.01; H, 5.66. TLC: Rf 0.20 (cyclohexane/EtOAc: 7/3). 
IR (neat) νmax/ cm-1: 3650, 2983, 2190, 1739, 1373, 1239, 1047. 1H NMR (300 MHz, CDCl3) δ ppm 7.10-7.03 (m, 2H), 6.9-6.8 (m, 
2H), 6.75 (s, 1H), 6.63 (d, J = 8.3 Hz, 1H), 6.53 (dd, J = 1.9 Hz, J = 8.4 Hz, 1H), 6.40 (s, 2H), 3.91 (s, 3H), 3.90 (s, 3H), 3.83 (s, 3H), 
3.71 (s, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 153.5 (2C), 152.1 (1C, d, J=244.49 Hz), 145.6, 144.9, 139.4, 137.5, 136.6, 136.5, 
135.4, 130.6, 126.9, 123.1, 121.7, 115.5, 114.6 (1C, d, J=19.19 Hz), 112.9, 110.1, 107.3 (2C), 61.1, 56.3, 56.1, 55.9. MS (ESI) m/z: 
587.1 (M+Na+). 
 
(Z)-5-(2-(3-Hydroxy-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl) vinyl)-2-methoxyphenol (1h) 
Yield: 97 %. Anal. calcd for 1h (C25H26O7): C, 68.48; H, 5.98. Found: C, 68.34; H, 5.88. TLC: Rf 0.29 (cyclohexane/EtOAc: 6/4). IR 
(neat) νmax/ cm-1: 2935, 1736, 1580, 1508, 1127, 1045. 1H NMR (300 MHz, CDCl3) δ ppm 6.88 (d, J = 1.6 Hz, 1H), 6.75-6.73 (m, 
2H), 6.69 (s, 1H), 6.57 (d, J = 1.6 Hz, 1H), 6.55 (d, J = 8.3 Hz, 1H), 6.44 (dd, J = 1.6 Hz, J = 8.4 Hz, 1H), 6.34 (s, 2H), 5.53 (s, 1H), 
5.38 (s, 1H), 3.83 (s, 3H), 3.82 (s, 3H), 3.75 (s, 3H), 3.63 (s, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 153.6 (2C), 16.3, 145.6, 145.4, 
145.1, 140.5, 137.5, 136.9, 135.9, 131.1, 126.5, 121.7, 119.4, 115.7, 113.7, 110.4, 110.3, 107.5 (2C), 61.2, 56.3, 56.1, 56.0. 
4.2 Biolology 
Cell Culture and Proliferation Assay.  
Cancer cell lines were obtained from the American type Culture Collection (Rockville, MD) and were cultured according to the 
supplier’s instructions. Briefly, A549 lung carcinoma, MDA-MB-231, MDA-MB-435 cells were grown in Dulbecco minimal 
essential medium (DMEM) containing 4.5 g/L glucose supplemented with 10% FCS and 1% glutamine.  HCT116 colorectal 
carcinoma cells were grown in RPMI 1640 containing 10% FCS and 1% glutamine. Cell lines were maintained at 37 °C in a 
humidified atmosphere containing 5% CO2. Cell viability was assessed using Promega CellTiter-Blue TM reagent according to the 
manufacturer’s instructions. Cells were seeded in 96-well plates (5 × 103 cells/well) containing 50 μL growth medium. After 24 h of 
culture, the cells were supplemented with 50 μL of the tested compound dissolved in DMSO (less than 0.1% in each preparation). 
After 72 h of incubation, 20 μL of resazurin was added for 2 h before recording fluorescence (λex = 560 nm, λem = 590 nm) using a 
Victor microtiter plate fluorimeter (Perkin-Elmer,USA). The IC50 corresponds to the concentration of the tested compound that 
caused a decrease of 50% in fluorescence of drug treated cells compared with untreated cells. Experiments were performed in 
triplicate. 
Tubulin Binding Assay 
Sheep brain tubulin was purified according to the method of Shelanski[57] by two cycles of assembly-disassembly and then 
dissolved in the assembly buffer containing 0.1 M MES, 0.5 mM MgCl2, 1 mM EGTA, and 1 mM GTP, pH 6.6 (the concentration of 
tubulin was about 2-3 mg/mL). Tubulin assembly was monitored and recorded continuously by turbidimetry at 350 nm in a UV 
spectrophotometer equipped with a thermostatted cell at 37°C. The GI50 value of each compound was determined as the 
concentration which decreased the maximum assembly rate of tubulin by 50% compared to the rate in the absence of compound. The 
GI50 values for all compounds were compared to the GI50 of CA4 and isoCA-4 and measured the same day under the same 
conditions. 
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Figure 1. Representative tubulin binding agents and general structure of the synthesized hybrids 1. 
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Scheme 1. Retrosynthetic pathway leading to triarylolefins 1 
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Scheme 2 Reagents and conditions : (a) PdCl2(PPh3)2 (2 mol%), Bu3SnH, (1.2 equiv), THF, 79%. (b) I2 (1 equiv), CH2Cl2, 
74%. (c) 3,4,5-(OMe)3C6H2ZnCl (2.2 equiv), PdCl2(PPh3)2 (5 mol%), THF, 99%. (d) 3,4,5-(OMe)3C6H2I (0.9 equiv), 
Pd(PPh3)4 (5 mol%), CuI (10 mol%), CsF (2 equiv), DMF, 60 °C, 54%. 
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Scheme 4. Synthesis of ortho bromodiarylalkynes 5. Reagents and conditions: (a) (i) HCCSiMe3 (1.5 equiv), CuI (10 mol%), 
PdCl2(PPh3)2 (5 mol%), piperidine, 20 °C; (ii) K2CO3, MeOH, 92%. (b) ArI (0.7 equiv), CuI (10 mol%), PdCl2(PPh3)2 (5 
mol%), Et3N/THF (1/1), 60 °C, 5a: 80%; 5b: 86%, 5c: 66%, 5d: 80%. (c) Br2, AcOH, 92%. (d) (i) HCCSiMe3 (1.5 equiv), 
CuI (10 mol%), PdCl2(PPh3)2 (5 mol%), Et3N/THF (1/1), 60 °C, (ii) K2CO3, MeOH, 72%.  
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Scheme 5. Synthesis of triarylolefins 1b-h. Reagents and conditions: (a) PdCl2(PPh3)2 (2 mol%), Bu3SnH, (1.2 equiv), 
THF. (b) I2 (1 equiv), CH2Cl2, 20 °C. (c) ArZnCl (2.2 equiv), PdCl2(PPh3)2 (5 mol%), THF. (d) (i) n-BuLi (4.5 equiv), 
THF, -78 °C. (ii) HCl 1M, 0.5 h, 20 °C. 
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Table 1. Cytotoxicity of isoCA on HCT 116 human cancer cell line and antitubulin activities. 
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10b 
Br
MeO OMe
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MeO OMe
OMeMeO
OMe
 MeO OMe
OMeMeO
OMe
MeO
OMe  
1a 1b 
Cytotoxicity 
IC50[a] [M] 
 
> 10-5 > 10-5 > 10-5 
ITP[b] 
IC50 [M] 8.0 8.1 NA 
 
 
Compounds 
MeO
OMe
OMeMeO
OMe
 MeO OMe
OMe
HO OMe
MeO  MeO OMe
Me
HO OMe
MeO  
 1c 1d 1e 
Cytotoxicity 
IC50[a] [M] 
 
> 10-5 > 10-5 3 10-6 
ITP[b] 
IC50 [M] 8.0 7.8 NA 
 
 
Compounds 
MeO OMe
HO OMe
MeO  MeO OMe
OMe
HO OMe
MeO
F
 MeO OMe
OMe
HO OMe
MeO
HO
 
 1f 1g 1h 
Cytotoxicity 
IC50[a] [M] 
 
8 10-6 8 10-6 5 10-6 
ITP[b] 
IC50 [M] NA NA 8.5 
References CA-4 isoCA-4  
Cytotoxicity 
IC50[a] [M] 
 
2 10-9 2 10-9  
ITP[b] 
IC50 [M] 1.0 2.1  
[a] IC50 is the concentration of compound needed to reduce cell growth by 50% following 72 h cell treatment with the 
tested drug (average of three experiments). [b] ITP = Inhibition of Tubulin Polymerization; IC50 is the concentration 
of compound required to inhibit 50% of the rate of microtubule assembly (average of three experiments). [c] NA, non 
active. 
 
 
 
 
 
 
